Pfizer recognized the Certified Physician Investigator designation obtained through the Association of Clinical Research Professionals' (ACRP) Certification Program as an acceptable method for clinical investigators to demonstrate competency in good clinical practice (GCP) for Pfizer-sponsored clinical trials.
The decision recognizes the importance of high-quality training in the tenets of GCP to promote physician investigators' safe and ethical conduct of clinical trials with human subjects. Pfizer has reviewed the ACRP Certification Program and says it will recognize the CPI® designation for investigators who wish to conduct Pfizer-sponsored clinical trials.
The examination taken by qualified physicians wishing to earn the CPI® designation is administered by the Academy of Clinical Research Professionals, an affiliate of ACRP that also oversees the Certified Clinical Research Coordinator (CCRC®) and Certified Clinical Research Associate (CCRA®) Certification Programs. The non-profit ACRP was founded in 1976 to promote integrity and excellence in the field and, since 1992, has been the leading certifier of clinical research professionals with more than 24,000 professionals, including nearly 1,100 CPIs, having earned a designation to date.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.